Submission of Cash Flow Statement in PDF for Standalone Financial Results for the respective period in complinace with the discrepancy raised by the Exchange.
Awaiting price reaction for this filing.
Nutraplus India Ltd, a single-segment Active Pharmaceutical Ingredient (API) manufacturer, submitted its audited standalone financial results for Q4 FY25 and full year FY25 to BSE after a delay flagged by the Exchange. The company reported a net loss of approximately Rs 6.16 lakh for FY25, wider than the Rs 5.01 lakh loss in FY24, with EPS remaining negative. The auditor issued a Qualified Opinion, citing the company's failure to comply with SEBI listing rules on timely submission of quarterly results and limited review reports. Worryingly, the company's balance sheet shows negative net worth of around Rs 5.39 crore (equity eroded), and the cash flow statement reveals that bank borrowings were reclassified from non-current to current liabilities due to default, with property already taken by a bank under SARFAESI action.
This is a negative filing for shareholders. The qualified audit opinion, persistent losses, negative book value, and SARFAESI/bank default signals all point to serious financial distress and going-concern risks. Retail investors should treat this as a high-risk micro-cap stock and watch for any further regulatory action or capital restructuring announcements.